Genesis Private Wealth LLC Invests $205,000 in Sanofi (NASDAQ:SNY)

Genesis Private Wealth LLC bought a new stake in shares of Sanofi (NASDAQ:SNY) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,250 shares of the company’s stock, valued at approximately $205,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Jennison Associates LLC boosted its stake in shares of Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares during the period. JPMorgan Chase & Co. increased its stake in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Franklin Resources Inc. raised its holdings in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after buying an additional 395,744 shares during the period. Finally, Barclays PLC raised its holdings in Sanofi by 107.5% during the 3rd quarter. Barclays PLC now owns 639,772 shares of the company’s stock worth $36,869,000 after buying an additional 331,445 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Shares of SNY stock opened at $51.51 on Thursday. The company has a market capitalization of $130.72 billion, a price-to-earnings ratio of 26.28, a P/E/G ratio of 1.25 and a beta of 0.57. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock’s fifty day simple moving average is $48.53 and its 200-day simple moving average is $52.16.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.55 EPS. On average, sell-side analysts predict that Sanofi will post 3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.